Core Insights - The article discusses the evolving trends in the Chinese marketing landscape leading up to 2025, highlighting shifts in consumer behavior driven by emotional, experiential, aesthetic, health, and smart consumption [3][4][12]. Emotional Consumption - Emotional consumption focuses on emotional resonance, social currency, and community identity, with brands creating emotional assets through storytelling and IP collaborations [17][19]. - The search rates for emotional consumption reached 20.3% in December 2025, indicating its significance in consumer decision-making [5]. Experiential Consumption - Experiential consumption emphasizes unique processes and feelings, with industries like tourism and outdoor activities integrating experience into their marketing strategies [36][38]. - The sportswear industry is shifting from selling products to promoting outdoor lifestyle experiences, with key content interactions in 2025 showing significant engagement in outdoor activities [61][62]. Aesthetic Consumption - Aesthetic consumption is characterized by consumers' willingness to pay a premium for beauty, impacting industries such as beauty and luxury goods [70][72]. - In December 2025, beauty-related content interactions reached 26.1%, showcasing the importance of aesthetics in consumer choices [6][74]. Health Consumption - Health consumption is increasingly integrated into daily life, with consumers prioritizing long-term health and wellness over reactive healthcare [95][97]. - The health management market is evolving, with brands focusing on daily health solutions and lifestyle integration [99][101]. Smart Consumption - Smart consumption is driven by technological innovation, enhancing efficiency, safety, and convenience in consumer experiences [113][114]. - The rise of AI applications is making smart services more accessible, with significant growth in user engagement and market penetration [118][120].

Core Insights - The article emphasizes the growing demand for probiotics, driven by new channels like Douyin and emerging needs such as weight loss, highlighting the potential of the second-generation probiotic AKK and the acceleration of market education by brands [2][3]. Group 1: Market Overview - Probiotics are widely applied across various sectors, with the current market size exceeding 100 billion. The probiotic health product market is projected to reach 16 billion by 2025, reflecting a year-on-year growth of 6%. Douyin's rapid growth contributes significantly, with GMV increasing nearly 40% [2]. - Pricing for probiotic health products typically ranges from 5 to 15 yuan per daily serving, with brands focusing on different formulations, strains, and benefits. Demand is shifting from basic gut health to weight loss and targeted care, prompting brands to expand their product lines. The top three brands, Wanyilan, Lifespace, and Nutrilite, each have retail sales exceeding 1 billion [2]. Group 2: Supply Chain Dynamics - The upstream of the probiotic industry is highly concentrated, with international giants like DuPont and Chr. Hansen holding over 80% market share due to years of developing star strains and research capabilities. The raw material segment has high added value, with key strains being crucial for pricing. Domestic leading manufacturers achieve gross margins of 40-60% and net margins of 20-30% [3]. - Domestic companies are increasingly focusing on research and development, aiming to advance the industrialization of core strains, including emerging strains like AKK. With sufficient production capacity, there is significant potential for local replacement as star strains mature [3]. Group 3: Future Prospects - The second-generation probiotic AKK is positioned to target weight loss, with brands accelerating market education. This generation of probiotics focuses on addressing specific health issues with clear mechanisms of action. AKK has shown promise in enhancing metabolism, immunity, and anti-aging, with its industrialization and marketization accelerating in recent years [3]. - The demand for weight loss probiotics is rapidly increasing, with sales in this category expected to grow by 45% year-on-year by 2025. Multiple brands are launching weight loss products, and AKK's extensive research and clinical validation in weight loss and metabolism enhancement suggest a broad market potential [3].

Group 1: Investor Relations Activity - The 2025 annual performance briefing was held online on March 30, 2026, from 15:00 to 16:00, targeting all investors [2] - The event was hosted on the Shenzhen Stock Exchange's "Interactive Easy Platform" [2] - Key company representatives included the General Manager Lin Zhicheng, Independent Director Liu Heng, Secretary of the Board Tang Jinyin, and CFO He Bailing [2] Group 2: Business Strategy and Focus Areas - In 2026, the company will continue to integrate e-commerce operations, focusing on interest e-commerce and cross-border e-commerce [2] - The operational strategy emphasizes high-quality content creation to empower platform operations and increase sales through self-controlled live streaming [2] - The product strategy includes strengthening new product investments, with multiple brands expanding into the Hong Kong market [2] Group 3: Challenges and Competitive Measures - The stagnation in online distribution and direct sales growth is attributed to changes in the external consumer environment, industry competition, and channel dynamics [3] - The company aims to enhance its core competencies in technology, product quality, brand strength, channel effectiveness, and service capabilities to consolidate and improve market share [3]

Core Viewpoint - NMN (β-Nicotinamide Mononucleotide) is gaining attention in the global health industry for its potential anti-aging, DNA repair, and metabolic regulation benefits, with significant developments in regulatory approval and market potential expected by 2025 [1][2]. Industry Development - The NMN industry has evolved from laboratory research to commercial applications, with major markets like the US, Japan, Canada, and Australia recognizing its legal status through various regulatory pathways [1][2]. - China is currently the largest producer of NMN raw materials, with leading companies building competitive barriers through technological innovation and industry chain layout [2]. NMN Definition and Function - NMN is a direct precursor to NAD+ (Nicotinamide Adenine Dinucleotide), crucial for delaying aging and enhancing physiological functions [3][4]. - Supplementing NMN can quickly elevate NAD+ levels in the body, playing a vital role in anti-aging, cardiovascular health, and metabolic improvement [4]. Synthesis Pathways - NMN supplementation shows significant advantages in NAD+ synthesis pathways compared to other precursors, with the highest conversion efficiency and no known adverse effects [6][7]. Natural Sources and Supplementation - Natural food sources of NMN are limited, making NMN supplements, which can provide up to 300 times the intake from dietary sources, more effective [8]. Synthesis Technology - The NMN synthesis process has shifted from chemical methods to fully enzymatic methods, which are safer, more efficient, and environmentally friendly [10][11]. - Leading companies are innovating in full enzymatic synthesis technology, creating competitive advantages through patent applications [12]. Market Trends and Drivers - The demand for NMN is driven by an aging population and increasing awareness of anti-aging among younger demographics, creating a dual market push [19]. - Technological advancements in synthesis, quality testing, and delivery methods are driving the NMN industry towards scale, standardization, and efficiency [21][22]. Application Areas - NMN is primarily used in health supplements and cosmetics, with potential future applications in pet nutrition, medical health, and agricultural technology [24][28]. - The NMN market in China is expected to exceed 3 billion yuan by 2025, with significant growth anticipated as regulatory barriers are lifted [28]. Sales Channels - NMN products are mainly sold through cross-border e-commerce and private channels, with cross-border platforms accounting for 60%-70% of market share [35]. Certification and Compliance - The "blue hat" certification for health supplements in China represents the highest standard for NMN products, with strict approval processes that could reshape the market landscape if achieved [37]. Challenges and Opportunities - The NMN industry faces challenges such as exaggerated claims, lack of consumer awareness, and technological iterations, necessitating compliance and innovation for long-term competitiveness [61][63]. - Companies are encouraged to innovate their business models, extending from raw material supply to comprehensive service providers across the entire industry chain [66].

Investment Rating - The report upgrades the investment rating to "Strong Buy" with a target price of HKD 16.00, compared to the current price of HKD 12.45 [2][8]. Core Insights - The company reported a revenue of HKD 14.354 billion for 2025, representing a year-on-year growth of 9.97%, with Q4 revenue growth of 3.4% [8]. - Adjusted EBITDA for 2025 was HKD 2.05 billion, up 5.0% year-on-year, while adjusted net profit reached HKD 664 million, a 22.7% increase [8]. - The company is expected to continue its growth trajectory in 2026, with a focus on product innovation and market expansion, particularly in the Swisse brand and high-end infant formula [8]. - The debt structure is improving, with a reduction in total debt and interest expenses, which is anticipated to enhance overall profitability [8]. Financial Performance Summary - For 2025, the company achieved an adjusted EBITDA margin of 14.3%, with a net profit margin of 4.6% [8]. - The net leverage ratio decreased from 3.99x to 3.45x, indicating a stronger balance sheet [8]. - The company expects revenue growth in 2026 to be in the high single to low double digits, with adjusted net profit margin targets around 5% [8]. Business Segment Performance - The ANC segment generated revenue of HKD 6.946 billion in 2025, growing 3.7% year-on-year, with Swisse maintaining the top market share in China and Australia [8]. - The BNC segment saw a robust revenue increase of 20.0% year-on-year, reaching HKD 5.257 billion, driven by strong growth in high-end infant formula [8]. - The PNC segment reported revenue of HKD 2.150 billion, up 9.0% year-on-year, with Zesty Paws experiencing a 12.8% growth in North America [8].

Group 1 - The report highlights concerns over global "stagflation," with market expectations shifting towards potential interest rate hikes within the year, leading to adjustments across various asset classes [2] - The analysis of 62 multinational companies operating in China indicates that 51% of them expect improved performance in Q4 2025, while 40% foresee potential declines [3] - Sectors such as finance, consumer goods, and healthcare show higher optimism regarding future performance, with notable growth in paint, food and beverage, and high-end beauty segments [3] Group 2 - The automotive sector report indicates that the economic viability of electric vehicles (EVs) compared to fuel vehicles is improving, particularly in Europe and Southeast Asia, which are expected to drive EV penetration [4] - The report on China Pacific Insurance shows a significant profit increase, with a net profit of HKD 27.1 billion in 2025, reflecting a 221% year-on-year growth, driven by improved investment performance [5] - China Telecom's revenue reached CNY 523.9 billion in 2025, with a net profit of CNY 33.2 billion, indicating a modest growth trajectory despite challenges in revenue acceleration [5] Group 3 - Yancoal Australia is positioned to benefit from a new cycle of coal prices, with production expected to reach historical highs in 2025, capitalizing on geopolitical tensions [6] - Kingsoft Office reported a revenue of CNY 5.929 billion in 2025, driven by successful AI strategy implementation, with a notable increase in active users [7] - Beijing Enterprises Water Group's revenue decreased to CNY 22.06 billion in 2025, but free cash flow significantly improved, indicating potential for future dividend increases [8] Group 4 - Yuyuan Group's revenue fell to CNY 36.37 billion in 2025, with a net loss of CNY 4.9 billion, attributed to asset impairment during its restructuring phase [9] - Kunlun Energy's revenue reached CNY 193.98 billion in 2025, with a proposed dividend of CNY 0.3198 per share, reflecting a commitment to shareholder returns despite a decline in net profit [9] - The report on 361 Degrees shows a revenue increase to CNY 11.15 billion in 2025, with a net profit of CNY 1.31 billion, supported by strong brand positioning and e-commerce growth [17] Group 5 - The report on China Chemical indicates a revenue of CNY 190.1 billion in 2025, with a net profit of CNY 6.44 billion, benefiting from successful execution of overseas projects and improved gross margins [32] - The analysis of Nongfu Spring reveals a revenue of CNY 52.55 billion in 2025, with a net profit of CNY 15.87 billion, driven by strong performance in packaged water and ready-to-drink tea segments [30] - The report on Ruifeng Power highlights a revenue of CNY 3.1 billion in 2025, with a net profit of CNY 410 million, reflecting growth in the clean energy sector [31]

Core Viewpoint - The Chinese health supplement industry is undergoing a significant transformation, shifting from a model targeting older consumers to one focused on younger demographics, with an emphasis on specific health needs and daily consumption [4][12][53]. Group 1: Industry Changes - The traditional model of health supplements, which relied on older consumers and gift-giving, is becoming less effective as younger consumers seek products that address specific health issues [8][10]. - The purchasing logic has shifted from a vague notion of "needing to supplement" to a clear focus on solving specific health problems, such as sleep issues or digestive discomfort [9][26]. - Consumers are now more informed and skeptical, preferring products that provide clear functional explanations and ingredient transparency rather than relying solely on brand reputation [11][21]. Group 2: Market Dynamics - The growth in the health supplement market is now driven by younger consumers who prioritize functionality, convenience, and daily use over traditional gift-giving practices [53][55]. - New brands that focus on specific health solutions and user-friendly formats are emerging, while traditional brands struggle to adapt to these changes [35][56]. - The competition is shifting from brand loyalty to solution-oriented offerings, where the ability to define and meet specific consumer needs becomes crucial for success [33][50]. Group 3: Product Innovation - Successful brands are those that can translate health supplements into consumer-friendly products that fit seamlessly into daily life, moving away from the heavy "medicinal" feel of traditional supplements [41][47]. - The industry is entering a "functional consumption era," where the emphasis is on clear usage scenarios and comprehensive solutions rather than vague health benefits [30][32]. - Brands that can simplify the decision-making process for consumers and create enjoyable consumption experiences are likely to thrive in this evolving market [44][48].

Summary of the Conference Call for Kingdawei Company and Industry Overview - **Company**: Kingdawei operates in the health supplement industry, uniquely covering the entire supply chain from raw materials to manufacturing and branding. [3] - **Market Position**: Kingdawei holds approximately 50% of the global market share for Coenzyme Q10 and has significant production capacity for Vitamins A and D. [3] Key Points and Arguments Financial Performance and Projections - **Revenue and Profit Growth**: Kingdawei expects revenue and profit growth rates between 10% and 20% in 2026, with a significant increase anticipated in 2028 as direct sales business is expected to explode. [2][14] - **Sales Performance**: The sales volume of Coenzyme Q10 is projected to increase by 10% to 15%, with a historical high in January 2026. [2][19] - **Doctor's Best Brand**: The brand's domestic GMV grew over 70% year-on-year in early 2026, exceeding market expectations. [2][17] - **Vitamin A Price Surge**: Due to geopolitical factors, Vitamin A prices increased by nearly 60% to 95 RMB/kg, potentially contributing an additional ten million RMB in profit. [2][20] Business Developments - **DHA Project**: The algae oil DHA project is ahead of schedule, expected to generate over 500 million RMB in annual revenue once fully operational, with an internal rate of return (IRR) exceeding 20%. [2][15] - **Zipfizz Brand Recovery**: The Zipfizz brand is anticipated to turn around in 2026 through new product launches and expansion via Costco channels. [2][18] Industry Dynamics - **Long-term Growth Drivers**: The health supplement industry is supported by an aging population and new consumption trends, with an expected annual growth rate of around 7% over the next three years. [6] - **E-commerce Role**: Cross-border e-commerce plays a crucial role, with nearly 60% of the Chinese health supplement market sales occurring online, half of which comes from cross-border e-commerce. [6] Additional Important Insights - **Production Capacity Expansion**: Kingdawei's production capacity for Coenzyme Q10 increased from 620 tons to 920 tons, which is expected to support future growth. [8][10] - **Market Demand for Coenzyme Q10**: The demand for Coenzyme Q10 is stable and expanding, with over 60% used in health supplements. [9][10] - **Vitamin A Market Characteristics**: The Vitamin A market is highly volatile, primarily driven by demand from feed additives and influenced by the pig cycle. Kingdawei acts as a price follower with limited bargaining power. [11][12] Conclusion Kingdawei is positioned for significant growth in the health supplement industry, with strong projections for revenue and profit increases driven by strategic brand management, production capacity expansion, and favorable market conditions. The company is also adapting to market dynamics and consumer trends, particularly through e-commerce channels.

Core Viewpoint - The company aims for double-digit revenue growth in 2026 after stabilizing in 2025, focusing on product innovation and channel expansion to drive performance recovery [7]. Group 1: Financial Performance - In 2025, the company achieved revenue of 6.27 billion yuan, a year-on-year decrease of 8.4%, while net profit attributable to shareholders was 780 million yuan, an increase of 19.8% [4]. - The fourth quarter of 2025 saw revenue of 1.35 billion yuan, a year-on-year increase of 22.2%, with a net profit loss of 130 million yuan, showing a reduction in losses [4]. - The main brand "汤臣倍健" generated revenue of 3.349 billion yuan in 2025, down 10.38% year-on-year, while the overseas LSG business performed well with revenue of 934 million yuan, up 16.43% [5]. Group 2: Channel Performance - Offline channel revenue in 2025 was 2.824 billion yuan, down 17.39% year-on-year, while online channel revenue was 3.372 billion yuan, up 0.28% year-on-year, indicating stabilization [5]. - The e-commerce channel has become a major force in the domestic market, accounting for over 60% of total sales in the VDS (Vitamins and Dietary Supplements) sector [5]. Group 3: Profitability and Cost Management - The company's gross margin for 2025 was 67.9%, up 1.21 percentage points year-on-year, benefiting from an increase in high-margin product revenue [6]. - The sales expense ratio for 2025 was 42.81%, down 1.52 percentage points year-on-year, while the management expense ratio was 8.07%, down 0.07 percentage points [6]. - The net profit margin for 2025 reached 13.03%, an increase of 3.56 percentage points year-on-year [6]. Group 4: Future Strategy - The company plans to adopt a "re-entrepreneurship" mindset starting in 2026, targeting double-digit revenue growth through product innovation and channel expansion [7]. - Key initiatives include launching new products, focusing on high-growth segments like fish oil and children's calcium, and expanding into high-end supermarkets and female-targeted products [7][8].

Investment Rating - The industry rating is maintained as "Positive" [1] Core Views - The report emphasizes a continued preference for strong alpha stocks and highlights the upcoming performance catalysts in the food and beverage sector [1][2] - The white liquor segment shows resilience, with Moutai leading the market, while the broader food and beverage sector is expected to experience performance catalysts in the near term [7][8] Market Performance Review - For the week of March 16-20, the food and beverage sector experienced a decline of -0.48%, while the Shanghai Composite Index and CSI 300 Index fell by -3.38% and -2.19%, respectively [15] - Specific segments such as white liquor (+0.32%) performed better compared to soft drinks (-0.69%), snacks (-4.40%), and pre-processed foods (-4.46%) [15] Weekly Updates White Liquor - The report continues to recommend Moutai, noting its strong performance amidst a defensive market preference [7] - Key companies like Jinhuijiu and Shede Liquor reported declines in revenue and net profit for 2025, with Moutai's market price showing slight fluctuations [7][8] Consumer Goods - Strong alpha companies with solid earnings are expected to see performance catalysts, with stocks like Dongpeng Beverage and Weidong Meishi showing positive trends [8][9] - The report highlights the potential for growth in the soft drink and dairy segments, driven by improving fundamentals and seasonal demand [8][9] Sector Investment Recommendations - In the white liquor sector, Moutai is the primary recommendation, with additional focus on brands like Luzhou Laojiao and Shanxi Fenjiu [9] - For consumer goods, the report recommends stocks such as Weidong Meishi, Salted Food, and Ximai Food, emphasizing their cost advantages and growth potential [9][12] Valuation Overview - As of March 21, 2026, the food and beverage sector's dynamic price-to-earnings ratio stands at 20.31 times, ranking 26th among primary industries [21] - Specific segments show varying valuations, with white liquor at 18.08 times and snacks at 32.39 times [21]